EXTON, Pa.--(BUSINESS WIRE)--Fibrocell Science, Inc. (NYSE MKT: FCSC), an autologous cell therapy company focused on the development of innovative products for aesthetic, medical and scientific applications, announced today that Chief Executive Officer and Chairman David Pernock, will preside over the Closing Bell on Tuesday, June 4, 2013 at 4 p.m. Eastern Time at the New York Stock Exchange.
“We are pleased that the New York Stock Exchange has given Fibrocell the honor of ringing the Closing Bell. This occasion marks the successful listing of our stock on the NYSE MKT,” Pernock said. “We are focused on expanding the applications of our FDA-approved product, LAVIV® (azficel-T), to areas of significant unmet medical needs such as restrictive burn scarring, vocal cord scarring and acne scarring.”
“In addition, we have entered into an exclusive channel collaboration (ECC) with Intrexon Corporation to explore the use of genetically-modified autologous fibroblast cells for Recessive Dystrophic Epidermolysis Bullosa, the most severe form of a debilitating genetic blistering disorder,” Pernock said.
The Closing Bell is televised live on CNBC and also airs online at https://nyse.nyx.com/the-bell/todays-bells-live at 4 p.m. ET. Web viewers may need to refresh their browsers ahead of 4 p.m. to start the live feed.
Photographs from the Closing Bell ceremony and a recording of the event, provided by NYSE, will be available on www.fibrocellscience.com on Wednesday, June 5, 2013.
About Fibrocell Science, Inc.
Fibrocell Science, Inc. (FCSC) is an autologous cell therapy company focused on the development of innovative products for aesthetic, medical and scientific applications. Fibrocell Science is committed to advancing the scientific, medical and commercial potential of autologous skin and tissue, as well as its innovative cellular processing technology and manufacturing excellence. For additional information, please visit www.fibrocellscience.com.
About LAVIV® (azficel-T)
LAVIV is the first and only autologous fibroblast cellular product approved by the FDA to improve the appearance of moderate to severe nasolabial fold (smile line) wrinkles in adults. It has been evaluated in more than 1,000 patients in clinical studies, including two pivotal Phase III trials. The safety and efficacy of LAVIV for areas other than the nasolabial folds have not been established. The efficacy of LAVIV beyond six months has not been established.
Important Safety Information about LAVIV® (azficel-T)
LAVIV (azficel-T) is an autologous cellular product for intradermal injection only. LAVIV is contraindicated for allogeneic use, in patients with allergy to gentamicin, amphotericin, dimethyl sulfoxide (DMSO) or material of bovine origin and in patients with active infection in the facial area. The following reactions have been reported following treatment with LAVIV: hypersensitivity reactions, bleeding and bruising at the treatment site, vasculitis, herpes labialis, basal cell cancer; keloid and hypertrophic scarring may occur following post-auricular skin biopsies or LAVIV injections. Additional warnings and precautions to be considered include the use of LAVIV in patients with genetic disorders or formation of normal collagen matrices and in immunosuppressed patients, or those patients undergoing chemotherapy for malignancies or receive immunomodulatory therapies for autoimmune diseases.
The most common adverse reactions, occurring in ≥1% of patients who receive LAVIV, were injection-site redness, bruising, swelling, pain, hemorrhage, edema, nodules, papules, irritation, dermatitis and pruritus.
For more information about LAVIV, please see the accompanying full Prescribing Information or visit www.mylaviv.com.
Forward-Looking Statements
All statements in this press release that are not based on historical fact are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 and the provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements include, without limitation, the Company’s ability to expand the indications of azficel-T into significant medical applications for which there are no currently approved medical options. While management has based any forward-looking statements contained herein on its current expectations, the information on which such expectations were based may change. These forward-looking statements rely on a number of assumptions concerning future events and are subject to a number of risks, uncertainties, and other factors, many of which are outside of the Company’s control, that could cause actual results to materially differ from such statements. Such risks, uncertainties, and other factors include, but are not necessarily limited to, those set forth under Item 1A “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2012, as updated in “Item 1A. Risk Factors” in the Company’s Quarterly Reports on Form 10-Q filed since the annual report. The Company operates in a highly competitive and rapidly changing environment, thus new or unforeseen risks may arise. Accordingly, investors should not place any reliance on forward-looking statements as a prediction of actual results. The Company disclaims any intention to, and undertakes no obligation to, update or revise any forward-looking statements. Readers are also urged to carefully review and consider the other various disclosures in the Company’s public filings with the SEC.
